Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2024 Oct 19

PMID 39425756

Authors

Zachary Braunstein

Jonathan E Brammer

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.

Recent Findings: Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.

References

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N . Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023; 141(18):2194-2205. PMC: 10356559. DOI: 10.1182/blood.2022018254. View

Cairns R, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais J . IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012; 119(8):1901-3. PMC: 3293643. DOI: 10.1182/blood-2011-11-391748. View

Coiffier B, Pro B, Prince H, Foss F, Sokol L, Greenwood M . Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7:11. PMC: 4016573. DOI: 10.1186/1756-8722-7-11. View

Braunstein Z, Ruiz M, Hanel W, Shindiapina P, Reneau J, Brammer J . Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas. J Pers Med. 2022; 12(6). PMC: 9225101. DOI: 10.3390/jpm12060964. View

Shimony S, Horowitz N, Ribakovsky E, Rozovski U, Avigdor A, Zloto K . Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Hematol Oncol. 2019; 37(5):569-577. DOI: 10.1002/hon.2691. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L . Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31(16):1970-6. DOI: 10.1200/JCO.2012.44.7524. View

Moskowitz A, Lunning M, Horwitz S . How I treat the peripheral T-cell lymphomas. Blood. 2014; 123(17):2636-44. PMC: 4507040. DOI: 10.1182/blood-2013-12-516245. View

Kanate A, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P . Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019; 5(5):715-722. PMC: 6988125. DOI: 10.1001/jamaoncol.2018.6278. View

10.

Amengual J, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E . A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2017; 131(4):397-407. PMC: 5790128. DOI: 10.1182/blood-2017-09-806737. View

11.

Kiel M, Velusamy T, Rolland D, Sahasrabuddhe A, Chung F, Bailey N . Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014; 124(9):1460-72. PMC: 4148768. DOI: 10.1182/blood-2014-03-559542. View

12.

Li N, Zhao D, Kirschbaum M, Zhang C, Lin C, Todorov I . HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A. 2008; 105(12):4796-801. PMC: 2290749. DOI: 10.1073/pnas.0712051105. View

13.

Ali H, Tsai N, Synold T, Mokhtari S, Tsia W, Palmer J . Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2021; 6(5):1444-1453. PMC: 8905711. DOI: 10.1182/bloodadvances.2021005035. View

14.

Kroger N, Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F . Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018; 24(10):2152-2156. DOI: 10.1016/j.bbmt.2018.05.023. View

15.

Jerez A, Clemente M, Makishima H, Koskela H, LeBlanc F, Ng K . STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012; 120(15):3048-57. PMC: 3471515. DOI: 10.1182/blood-2012-06-435297. View

16.

Horwitz S, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M . Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2017; 131(8):888-898. PMC: 5824337. DOI: 10.1182/blood-2017-08-802470. View

17.

Savage K, Horwitz S, Advani R, Haaber Christensen J, Domingo-Domenech E, Rossi G . Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022; 6(19):5550-5555. PMC: 9647727. DOI: 10.1182/bloodadvances.2020003971. View

18.

Ellin F, Landstrom J, Jerkeman M, Relander T . Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124(10):1570-7. DOI: 10.1182/blood-2014-04-573089. View

19.

ANDERSON J, Armitage J, Weisenburger D . Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998; 9(7):717-20. DOI: 10.1023/a:1008265532487. View

20.

Tao R, de Zoeten E, Ozkaynak E, Chen C, Wang L, Porrett P . Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007; 13(11):1299-307. DOI: 10.1038/nm1652. View